1. The novel three-way variant t(6;17;15)(p21;q21;q22) in acute promyelocytic leukemia with an FLT3-ITD mutation: A case report
- Author
-
Shu‑Qing Luan, Mei Jiang, Yong‑Lu Zhang, Jin‑Hua Wan, La‑Gen Wan, Zhang‑Lin Zhang, and Shu‑Yuan Liu
- Subjects
Acute promyelocytic leukemia ,Cancer Research ,Mutation ,Oncogene ,business.industry ,Retinoic acid ,Chromosomal translocation ,Articles ,Gene mutation ,medicine.disease_cause ,medicine.disease ,chemistry.chemical_compound ,Retinoic acid receptor ,Oncology ,chemistry ,immune system diseases ,medicine ,Cancer research ,Arsenic trioxide ,business ,neoplasms - Abstract
Acute promyelocytic leukemia (APL) is characterized by the reciprocal translocation t(15;17)(q22;q21), resulting in the fusion of the promyelocytic leukemia gene at 15q22 with the retinoic acid receptor α at 17q21. Additionally, all patients with APL who have additional chromosome abnormalities (ACA) and gene mutations are resistant to all-trans retinoic acid (ATRA), the drug that causes disease regression specifically in patients with APL globally. The present study describes a case of a 19-year-old female with APL carrying a novel complex variant translocation t(6;17;15)(p21;q21;q22), add(7)(q32) and an FMS-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation. Complete remission was attained following a course of chemotherapy with ATRA and arsenic trioxide. To the best of our knowledge, this is the first report of a novel three-way translocation of 6p21 and a FLT3-ITD mutation involved with APL.
- Published
- 2017